(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 May 2013 (16.05.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/071151 A1

(51) International Patent Classification:
C12N 5/00 (2006.01)

(21) International Application Number:
PCT/US2012/064508

(22) International Filing Date:
9 November 2012 (09.11.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/558,740 11 November 2011 (11.11.2011) US

(71) Applicant: **ESSENTIAL PHARMACEUTICALS, LLC** [US/US]; 770 Newton Yardley Road, Suite 212, Newtown, PA 18940 (US).

(72) Inventors: **ELHOFY, Adam**; 770 Newton Yardley Road, Suite 212, Newtown, PA 18940 (US). **WEBER, Allan**; 770 Newton Yardley Road, Suite 212, Newtown, PA 18940 (US).

(74) Agent: **NEVILLE, Katherine L.**; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: KIT COMPRISING SERUM REPLACEMENT AND LABILE FACTORS




FIG. 1

(57) **Abstract**: The present disclosure relates, in general to a kit comprising a serum replacement and one or more labile factors, such as growth factors, packaged separately in the kit. It is contemplated that the kit provides advantages to improve cell growth in culture compared to cells cultured not using the kit described herein.

WO 2013/071151 A1